Delivering a STINGing Blow to Small Cell Lung Cancer via Synergistic Inhibition of DNA-Damage Response and Immune-Checkpoint Pathways

Cancer Discov. 2019 May;9(5):584-586. doi: 10.1158/2159-8290.CD-19-0234.

Abstract

Small cell lung cancer (SCLC) has demonstrated modest responses to immune-checkpoint blockade despite harboring a high mutational burden. In this issue, Sen and colleagues show remarkable synergy between inhibition of the DNA-damage response and the PD-1 axis, resulting in striking tumor regressions in SCLC mouse models.See related article by Sen et al., p. 646.

Publication types

  • Comment

MeSH terms

  • Animals
  • DNA
  • DNA Damage
  • Lung Neoplasms / genetics*
  • Mice
  • Small Cell Lung Carcinoma / genetics*
  • T-Lymphocytes

Substances

  • DNA